Miriam J Smith1, Soomin Ahn2, Jung-Il Lee3, Michael Bulman1, Daniel du Plessis4, Yeon-Lim Suh5. 1. Manchester Centre for Genomic Medicine, Manchester Academic Health Sciences Centre (MAHSC), St Mary's Hospital, University of Manchester, Manchester, UK. 2. Department of Pathology, Ewha Womans University School of Medicine, Seoul, Korea. 3. Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 4. Department of Cellular Pathology and Greater Manchester Neurosciences Centre, Salford Royal Hospitals NHS Foundation Trust, Salford, UK. 5. Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Abstract
AIMS: Clear cell meningioma (CCM) is a rare subtype of meningioma and shows not only unusual histology, but also unique clinical features. Recently, SMARCE1 mutations have been shown to cause spinal and cranial CCMs. We present 12 cases which were diagnosed with CCM in a single institution between 1997 and 2014, and investigate their SMARCE1 mutation status. METHODS AND RESULTS: To investigate the SMARCE1 mutation status of these tumours, we used a combination of Sanger sequencing and multiplex ligation-dependent probe amplification analysis and also performed SMARCE1 immunohistochemical staining. We found both SMARCE1 mutational hits, including novel SMARCE1 mutations, in six of eight tested patients. Immunohistochemical analysis showed loss of SMARCE1 protein staining in all but two cases. Two individuals who were diagnosed originally with CCM were negative for SMARCE1 mutations, but tested positive for NF2 mutations. As a result, these two tumours were re-analysed and eventually reclassified, as a microcystic and a mixed pattern of meningothelial meningioma with focal clear cell areas, respectively. CONCLUSIONS: These results expand the spectrum of pathogenic variants in SMARCE1 and show that mutation screening can help to facilitate meningioma classification. This may have implications for prognosis and future clinical management of patients, as CCMs are classed as grade II tumours, while microcystic and meningothelial meningiomas are classed as grade I.
AIMS: Clear cell meningioma (CCM) is a rare subtype of meningioma and shows not only unusual histology, but also unique clinical features. Recently, SMARCE1 mutations have been shown to cause spinal and cranial CCMs. We present 12 cases which were diagnosed with CCM in a single institution between 1997 and 2014, and investigate their SMARCE1 mutation status. METHODS AND RESULTS: To investigate the SMARCE1 mutation status of these tumours, we used a combination of Sanger sequencing and multiplex ligation-dependent probe amplification analysis and also performed SMARCE1 immunohistochemical staining. We found both SMARCE1 mutational hits, including novel SMARCE1 mutations, in six of eight tested patients. Immunohistochemical analysis showed loss of SMARCE1 protein staining in all but two cases. Two individuals who were diagnosed originally with CCM were negative for SMARCE1 mutations, but tested positive for NF2 mutations. As a result, these two tumours were re-analysed and eventually reclassified, as a microcystic and a mixed pattern of meningothelial meningioma with focal clear cell areas, respectively. CONCLUSIONS: These results expand the spectrum of pathogenic variants in SMARCE1 and show that mutation screening can help to facilitate meningioma classification. This may have implications for prognosis and future clinical management of patients, as CCMs are classed as grade II tumours, while microcystic and meningothelial meningiomas are classed as grade I.
Authors: Philipp Sievers; Martin Sill; Christina Blume; Arnault Tauziede-Espariat; Daniel Schrimpf; Damian Stichel; David E Reuss; Helin Dogan; Christian Hartmann; Christian Mawrin; Martin Hasselblatt; Walter Stummer; Uta Schick; Jürgen Hench; Stephan Frank; Ralf Ketter; Leonille Schweizer; Jens Schittenhelm; Stéphanie Puget; Sebastian Brandner; Zane Jaunmuktane; Benno Küsters; Zied Abdullaev; Melike Pekmezci; Matija Snuderl; Miriam Ratliff; Christel Herold-Mende; Andreas Unterberg; Kenneth Aldape; David W Ellison; Pieter Wesseling; Guido Reifenberger; Wolfgang Wick; Arie Perry; Pascale Varlet; Stefan M Pfister; David T W Jones; Andreas von Deimling; Felix Sahm Journal: Acta Neuropathol Date: 2020-12-14 Impact factor: 17.088
Authors: Elmar Kirches; Felix Sahm; Andrey Korshunov; Stefan M Pfister; Christian Mawrin; Christina Bluecher; Natalie Waldt; Siegfried Kropf; Daniel Schrimpf; Philipp Sievers; Damian Stichel; Ulrich Schüller; Jens Schittenhelm; Markus J Riemenschneider; Matthias A Karajannis; Arie Perry; Torsten Pietsch; Svenja Boekhoff; David Capper; Katja Beck; Nagarajan Paramasivam; Matthias Schlesner; Priscilla K Brastianos; Hermann L Müller Journal: Acta Neuropathol Date: 2021-09-08 Impact factor: 17.088
Authors: Daniel M Fountain; Miriam J Smith; Claire O'Leary; Omar N Pathmanaban; Federico Roncaroli; Nicoletta Bobola; Andrew T King; Dafydd Gareth Evans Journal: Oncogene Date: 2020-12-01 Impact factor: 9.867